Q2 2026 saw robust sales and margin growth, with EPS and Adjusted EBITDA rising year-over-year. FY2026 guidance was raised for EPS, sales, and EBITDA, reflecting strong momentum. Share repurchases and disciplined capital allocation continued.Original document: Henry Schein, Inc. [HSIC] SEC 8-K Curr…
Henry Schein reported second-quarter 2026 results with total net sales of $3.458 billion and GAAP diluted EPS of $0.82, compared with $0.70 in Q2 2025. Non-GAAP diluted EPS was $1.27 versus $1.10 a year earlier, and Adjusted EBITDA for the quarter rose to $288 million. The company raised its FY2026…
Dental and medical products company Henry Schein NASDAQ:HSICwill be reporting results this Tuesday before the bell. Here’s what you need to know.Henry Schein beat analysts’ revenue expectations last quarter, reporting revenues of $3.37 billion, up 6.3% year on year. It was a mixed quarter for the c…
